Skip to main content

Find Clinical Trials

Home
Conditions
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial condition

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Explore clinical trials studying Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Study availability and eligibility vary by location and protocol.

3 public trials 2 recruiting studies

Refine in advanced search Browse all conditions

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma trial results

Recruiting

Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

NCT06649474

Conditions: Adenocarcinoma, Carcinoma, Digestive System Diseases, +14 more
Locations: CHU Estaing de Clermont-Ferrand Clermont-Ferrand, France

View Trial Details

Recruiting

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05960955

Conditions: Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Locations: Tianjin Provincial Tumor Hospital Tianjin, China

View Trial Details

Completed

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

NCT04221555

Conditions: Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Locations: Asan Medical Center Seoul, South Korea

View Trial Details